Capillary electrophoresis mass spectrometry

Human Metabolome Technologies (HMT) specializes in advanced metabolomic profiling, offering a range of platforms designed to analyze small molecules and their roles in health, disease, and various biological processes. Their innovative approaches include untargeted and quantitative solutions that leverage over 20 years of experience in the field. HMT's platforms, such as the OMEGA Scan and LC-OMEGA, utilize techniques like Capillary Electrophoresis-Mass Spectrometry (CE-MS) and high-resolution chromatography to measure a diverse array of metabolites, including polar and lipophilic compounds. This comprehensive profiling is essential for applications in cancer metabolism, neurobiology, and biomarker discovery, among others.

HMT emphasizes collaboration with clients to tailor their services to specific research goals, ensuring accurate and meaningful metabolic data interpretation. Their offerings include targeted panels for amino acids, lipid mediators, and glycolytic pathways, as well as specialized assays for cellular metabolism and sample quality analysis. By integrating various methods, HMT can provide extensive coverage of metabolites from different biological sources, facilitating a deeper understanding of metabolic pathways and their implications in health and disease.

United States

Human Metabolome Technologies (HMT) is a Japan-headquartered biotechnology company founded in 2003 and global leader in capillary electrophoresis-mass spectrometry (CE-MS) based metabolome analysis. We established our United States headquarters in Boston, MA in 2012 and have spent the last 8 years developing solutions for a broad range of research endeavors in pharma, biotech, and food production.

Human Metabolome Technologies

Company Details